Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors

NCT06849921 · clinicaltrials.gov ↗

NA

Phase

ACTIVE_NOT_RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors
Hematologic Disease

Interventions

DRUG: Cellular Therapy

Sponsor

Ruijin Hospital